{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:56:11Z","timestamp":1790780171621,"version":"4.1.0"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012465","name":"Nemours Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012465","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:p>\n                    Disorders affecting cartilage and bone development frequently originate from disrupted endochondral ossification within growth-plate cartilage. Nonetheless, few therapeutic interventions directly target the local signaling pathways governing this process. This review explores the C-type natriuretic peptide (CNP)\/natriuretic peptide receptor B (NPR-B) axis as a mechanism-based therapeutic approach addressing issues in cartilage and bone, including skeletal dysplasias, genetic short-stature conditions, and acquired ailments such as bone fractures. It summarizes the production and processing of CNP\n                    <jats:italic>in vivo<\/jats:italic>\n                    , elucidates how NPR-B activation induces cyclic guanosine monophosphate signaling in chondrocytes, and discusses how this pathway functionally antagonizes FGFR3-driven MAPK signaling in achondroplasia. Additionally, it traces the progression from native, rapidly cleared CNP peptides to engineered agonists optimized for enhanced stability, prolonged systemic exposure, or tissue retention, emphasizing exposure design. Clinically approved agents, such as vosoritide and navepegritide, exemplify how NPR-B agonism has become a viable treatment strategy for pediatric achondroplasia. Both U.S. approvals were accelerated, with final-height confirmation required. Emerging long-acting analogs, sustained-release prodrugs, matrix-binding constructs, Fc-fusion proteins, and elastin-like polypeptide fusion platforms demonstrate the potential for molecular design adaptations to meet various therapeutic objectives. The scope of potential applications now extends to hypochondroplasia, several non-achondroplasia genetic short-stature disorders, acquired growth-plate impairments, fracture healing, and osteoarthritis-related cartilage strategies. Overall, NPR-B agonism signifies a transition from systemic endocrine-driven growth promotion to the controlled modulation of skeletal growth and repair. Future developments will necessitate long-term evidence concerning final height, skeletal proportions, functional outcomes, joint health, quality of life, and safety.\n                  <\/jats:p>","DOI":"10.3389\/fchem.2026.1949456","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:08:02Z","timestamp":1790777282000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging NPR-B agonists for cartilage and bone: from CNP biology to translational compound design"],"prefix":"10.3389","volume":"14","author":[{"given":"Yasuhiko","family":"Ago","sequence":"first","affiliation":[{"name":"Department of Biomedical Research, Nemours Children\u2019s Health","place":["Wilmington, DE, United States"]},{"name":"Department of Pediatrics, Thomas Jefferson University","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amali","family":"Karunathilaka","sequence":"additional","affiliation":[{"name":"Department of Biomedical Research, Nemours Children\u2019s Health","place":["Wilmington, DE, United States"]},{"name":"Department of Biological Sciences, University of Delaware","place":["Newark, DE, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacky M.","family":"Guerrero-Vargas","sequence":"additional","affiliation":[{"name":"Department of Biomedical Research, Nemours Children\u2019s Health","place":["Wilmington, DE, United States"]},{"name":"Department of Pediatrics, Thomas Jefferson University","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Tomatsu","sequence":"additional","affiliation":[{"name":"Department of Biomedical Research, Nemours Children\u2019s Health","place":["Wilmington, DE, United States"]},{"name":"Department of Biological Sciences, University of Delaware","place":["Newark, DE, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.3390\/ijms26104940","article-title":"Identification of surrogate biomarkers for mucopolysaccharidosis type IVA","volume":"26","author":"Ago","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B61","unstructured":"Nda 219164 Accelerated Approval\n          \n          \n            \n              Author Anonymous"},{"key":"B89","unstructured":"YUVIWEL\u00ae (navepegritide) for injection, for subcutaneous use\n          \n          \n            \n              Author Anonymous"},{"key":"B5","unstructured":"BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance\n          \n          \n            \n              Author Anonymous"},{"key":"B6","unstructured":"BioMarin Reports Second Quarter 2026 Financial and Operating Results\n          \n          \n            \n              Author Anonymous"},{"key":"B7","unstructured":"BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance1 for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS\n          \n          \n            \n              Author Anonymous"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1294748","DOI":"10.3389\/fcell.2023.1294748","article-title":"Unveiling the pathogenic mechanisms of NPR2 missense variants: insights into the genotype-associated severity in acromesomelic dysplasia and short stature","volume":"11","author":"Badawi","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1086\/422013","article-title":"Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type maroteaux","volume":"75","author":"Bartels","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"A618","DOI":"10.1210\/jendso\/bvac150.1282","article-title":"OR18-5 A prospective clinical trial of vosoritide in selected genetic causes of short stature","volume":"6","author":"Boucher","year":"2022","journal-title":"J. Endocr. Soc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"H326","DOI":"10.1152\/ajpheart.1995.269.1.h326","article-title":"Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide","volume":"269","author":"Brandt","year":"1995","journal-title":"Am. J. Physiology-Heart Circulatory Physiology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/01.hyp.30.2.184","article-title":"Neutral endopeptidase regulates C-Type natriuretic peptide metabolism but does not potentiate its bioactivity in vivo","volume":"30","author":"Brandt","year":"1997","journal-title":"Hypertension"},{"key":"B11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1124\/jpet.119.258251","article-title":"TransCon CNP, a sustained-release C-Type natriuretic peptide prodrug, a potentially safe and efficacious new therapeutic modality for the treatment of comorbidities associated with fibroblast growth factor receptor 3\u2013Related skeletal dysplasias","volume":"370","author":"Breinholt","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/art.38199","article-title":"Protective effects of c-type natriuretic peptide on linear growth and articular cartilage integrity in a mouse model of inflammatory arthritis","volume":"66","author":"B\u00fck\u00fclmez","year":"2014","journal-title":"Arthritis and Rheumatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40262-021-01059-1","article-title":"Pharmacokinetics and exposure\u2013response of vosoritide in children with achondroplasia","volume":"61","author":"Chan","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/341068a0","article-title":"Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases","volume":"341","author":"Chang","year":"1989","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13023-023-02757-8","article-title":"Novel pathogenic NPR2 variants in short stature patients and the therapeutic response to rhGH","volume":"18","author":"Chen","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1101\/gad.1224204","article-title":"Cyclic GMP-dependent protein kinase II is a molecular switch from proliferation to hypertrophic differentiation of chondrocytes","volume":"18","author":"Chikuda","year":"2004","journal-title":"Genes and Dev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1159\/000339677","article-title":"Response to growth hormone therapy in children with Noonan syndrome: correlation with or without PTPN11 gene mutation","volume":"77","author":"Choi","year":"2012","journal-title":"Hormone Res. Paediatr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1073\/pnas.071389098","article-title":"Dwarfism and early death in mice lacking C-type natriuretic peptide","volume":"98","author":"Chusho","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"102591","DOI":"10.1016\/j.eclinm.2024.102591","article-title":"Vosoritide treatment for children with hypochondroplasia: a phase 2 trial","volume":"71","author":"Dauber","year":"2024","journal-title":"eClinicalMedicine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1210\/clinem\/dgag157","article-title":"A phase II basket trial of vosoritide in children with RASopathies, ACAN, and NPR2 deficiency","volume":"111","author":"Dauber","year":"2026","journal-title":"J. Clin. Endocrinol. and Metabolism"},{"key":"B21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000496544","article-title":"Plasma C-Type natriuretic peptide: emerging applications in disorders of skeletal growth","volume":"90","author":"Espiner","year":"2019","journal-title":"Hormone Res. Paediatr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"109417","DOI":"10.1016\/j.ymgme.2025.109417","article-title":"Early efficacy of vosoritide for the treatment of growth deficits in MPS IVA and VI","volume":"147","author":"Fung","year":"2026","journal-title":"Mol. Genet. Metabolism"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000537743","article-title":"C-Type natriuretic peptide analogs: current and future therapeutic applications","volume":"98","author":"Galetaki","year":"2024","journal-title":"Hormone Res. Paediatr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000542102","article-title":"Phase 2 trial of vosoritide use in patients with hypochondroplasia: a pharmacokinetic\/pharmacodynamic analysis","volume":"99","author":"Galetaki","year":"2026","journal-title":"Hormone Res. Paediatr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"10729","DOI":"10.1016\/s0021-9258(17)34119-4","article-title":"Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B","volume":"269","author":"Hagiwara","year":"1994","journal-title":"J. Biol. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"E1988","DOI":"10.1210\/jc.2013-2358","article-title":"An activating mutation in the kinase homology domain of the natriuretic peptide Receptor-2 causes extremely tall stature without skeletal deformities","volume":"98","author":"Hannema","year":"2013","journal-title":"J. Clin. Endocrinol. and Metabolism"},{"key":"B27","author":"Hardy","year":"2025"},{"key":"B28","author":"Hardy","year":"2026"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e198959","DOI":"10.1172\/jci.insight.198959","article-title":"Collagen-binding C-type natriuretic peptide enhances chondrogenesis and osteogenesis","volume":"11","author":"Hirai","year":"2025","journal-title":"JCI Insight"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0204172","DOI":"10.1371\/journal.pone.0204172","article-title":"Exogenous C-type natriuretic peptide restores normal growth and prevents early growth plate closure in its deficient rats","volume":"13","author":"Hirota","year":"2018","journal-title":"PLoS ONE"},{"key":"B31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fendo.2014.00201","article-title":"Natriuretic hormones in brain function","volume":"5","author":"Hodes","year":"2014","journal-title":"Front. Endocrinol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s10354-020-00741-6","article-title":"New developments in the management of achondroplasia","volume":"170","author":"H\u00f6gler","year":"2020","journal-title":"Wien. Med. Wochenschr."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1210\/jcem.78.6.8200946","article-title":"Bioactivity and metabolism of C-type natriuretic peptide in normal man","volume":"78","author":"Hunt","year":"1994","journal-title":"J. Clin. Endocrinol. and Metabolism"},{"key":"B34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/hmg\/ddy333","article-title":"C-type natriuretic peptide improves growth retardation in a mouse model of cardio-facio-cutaneous syndrome","volume":"28","author":"Inoue","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.biocel.2018.07.004","article-title":"Molecular and in silico analyses validates pathogenicity of homozygous mutations in the NPR2 gene underlying variable phenotypes of acromesomelic dysplasia, type maroteaux","volume":"102","author":"Irfanullah","year":"2018","journal-title":"Int. J. Biochem. and Cell Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/0006-291x(92)92257-x","article-title":"Isolation and identification of C-type natriuretic peptide in human monocytic cell line, THP-1","volume":"189","author":"Ishizaka","year":"1992","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B37","volume-title":"Elp Fusion Proteins For Controlled And Sustained Release","author":"James","year":"2017"},{"key":"B38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ajhg.2025.12.006","article-title":"Functional analysis of NPR2 variants supports the therapeutic rationale for CNP in short stature","volume":"113","author":"Jeong","year":"2026","journal-title":"Am. J. Hum. Genet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"P371","DOI":"10.1161\/res.129.suppl_1.p371","article-title":"Abstract P371: fusion of C-type natriuretic peptide with elastin-like polypeptide for enhanced pharmacological activity","volume":"129","author":"Jowett","year":"2021","journal-title":"Circulation Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0277140","DOI":"10.1371\/journal.pone.0277140","article-title":"Circulatory C-type natriuretic peptide reduces mucopolysaccharidosis-associated craniofacial hypoplasia in vivo","volume":"17","author":"Kashiwagi","year":"2022","journal-title":"PLOS ONE"},{"key":"B41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1210\/clinem\/dgaa842","article-title":"Clinical characteristics of short-stature patients with an NPR2 mutation and the therapeutic response to rhGH","volume":"106","author":"Ke","year":"2021","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"B42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-2350-13-44","article-title":"Novel mutations in natriuretic peptide receptor-2 gene underlie acromesomelic dysplasia, type maroteaux","volume":"13","author":"Khan","year":"2012","journal-title":"BMC Med. Genet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/07391102.2009.10507261","article-title":"The membrane proximal extracellular domain of human hGC-B folds independently","volume":"26","author":"Knake","year":"2009","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B44","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1126\/science.1672777","article-title":"Selective activation of the B natriuretic peptide receptor by C-Type natriuretic peptide (CNP)","volume":"252","author":"Koller","year":"1991","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1210\/en.2014-1801","article-title":"Increased bone turnover and possible accelerated fracture healing in a murine model with an increased circulating C-Type natriuretic peptide","volume":"156","author":"Kondo","year":"2015","journal-title":"Endocrinology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s11055-016-0328-4","article-title":"C-Type natriuretic peptide: what, where and why?","volume":"46","author":"Korostyshevskaya","year":"2016","journal-title":"Neurosci. Behav. Physiology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"dgaa190","DOI":"10.1210\/clinem\/dgaa190","article-title":"An activating deletion variant in the submembrane region of natriuretic peptide Receptor-B causes tall stature","volume":"105","author":"Lauffer","year":"2020","journal-title":"J. Clin. Endocrinol. and Metabolism"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","article-title":"Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia","volume":"91","author":"Lorget","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"109534","DOI":"10.1016\/j.ymgme.2025.109534","article-title":"Effect of vosoritide on bone biomarkers in prepubertal children with mucopolysaccharidosis types IVA and VI","volume":"147","author":"Lynch","year":"2026","journal-title":"Mol. Genet. Metabolism"},{"key":"B50","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jconrel.2014.06.028","article-title":"Applications of elastin-like polypeptides in drug delivery","volume":"190","author":"MacEwan","year":"2014","journal-title":"J. Control. Release"},{"key":"B51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13023-023-02652-2","article-title":"Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study","volume":"18","author":"Maghnie","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"B52","article-title":"BMN 333 achieves high sustained released vosoritide exposure with favorable safety: phase 1 results that support phase 2\/3 trials in achondroplasia","author":"Mitchell","year":"2026"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1210\/en.2002-220307","article-title":"Cyclic GMP-dependent protein kinase II plays a critical role in C-Type natriuretic peptide-mediated endochondral ossification","volume":"143","author":"Miyazawa","year":"2002","journal-title":"Endocrinology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000548836","article-title":"Thanatophoric dysplasia type 1 treated with vosoritide: a case report","author":"Montero-Lopez","year":"2025","journal-title":"Hormone Res. Paediatr."},{"key":"B55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.peptides.2017.09.008","article-title":"Design and evaluation of novel natriuretic peptide derivatives with improved pharmacokinetic and pharmacodynamic properties","volume":"97","author":"Morozumi","year":"2017","journal-title":"Peptides"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e0212680","DOI":"10.1371\/journal.pone.0212680","article-title":"ASB20123: a novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism","volume":"14","author":"Morozumi","year":"2019","journal-title":"PLoS ONE"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.3390\/ijms20092281","article-title":"C-Type natriuretic peptide: a multifaceted paracrine regulator in the heart and vasculature","volume":"20","author":"Moyes","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"bvae177","DOI":"10.1210\/jendso\/bvae177","article-title":"Treatment of short stature in aggrecan-deficient patients with recombinant human GH: 3-Year response","volume":"8","author":"Muthuvel","year":"2024","journal-title":"J. Endocr. Soc."},{"key":"B59","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/biology11070986","article-title":"CNP, the third natriuretic peptide: its biology and significance to the cardiovascular system","volume":"11","author":"Nakagawa","year":"2022","journal-title":"Biology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"10554","DOI":"10.1038\/srep10554","article-title":"The local CNP\/GC-B system in growth plate is responsible for physiological endochondral bone growth","volume":"5","author":"Nakao","year":"2015","journal-title":"Sci. Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1161\/01.hyp.19.6.809","article-title":"Human C-type natriuretic peptide. Characterization of the gene and peptide","volume":"19","author":"Ogawa","year":"1992","journal-title":"Hypertension"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1093\/hmg\/ddt162","article-title":"The Ras-GTPase activity of neurofibromin restrains ERK-dependent FGFR signaling during endochondral bone formation","volume":"22","author":"Ono","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"B64","doi-asserted-by":"publisher","first-page":"109580","DOI":"10.1016\/j.ymgme.2025.109580","article-title":"MRI diffusion tensor imaging of distal femoral and proximal tibial growth plates in MPS: quantitative response to vosoritide","volume":"147","author":"Perdomo-Luna","year":"2026","journal-title":"Mol. Genet. Metabolism"},{"key":"B65","volume-title":"Compositions Comprising Alkaline Phosphatase And\/Or Natriuretic Peptide And Methods Of Use Thereof","author":"Philippe","year":"2013"},{"key":"B66","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1210\/er.2005-0014","article-title":"Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions","volume":"27","author":"Potter","year":"2006","journal-title":"Endocr. Rev."},{"key":"B67","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/978-3-540-68964-5_15","article-title":"Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications","author":"Potter","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"9890","DOI":"10.3390\/ijms24129890","article-title":"Bone growth induction in mucopolysaccharidosis IVA mouse","volume":"24","author":"Rintz","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/nejmoa1813446","article-title":"C-Type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Savarirayan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/s0140-6736(20)31541-5","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"Savarirayan","year":"2020","journal-title":"Lancet"},{"key":"B71","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1001\/jamapediatrics.2025.4771","article-title":"Once-weekly navepegritide in children with achondroplasia","volume":"180","author":"Savarirayan","year":"2026","journal-title":"JAMA Pediatr."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e2201067119","DOI":"10.1073\/pnas.2201067119","article-title":"A long-acting C-natriuretic peptide for achondroplasia","volume":"119","author":"Schneider","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1210\/jc.2016-2941","article-title":"ACAN gene mutations in short children born SGA and response to growth hormone treatment","volume":"102","author":"Steen","year":"2017","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"B74","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/332078a0","article-title":"A new natriuretic peptide in porcine brain","volume":"332","author":"Sudoh","year":"1988","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1210\/endo.133.6.8243333","article-title":"Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells\u2014evidence for CNP as a novel autocrine\/paracrine regulator from endothelial cells","volume":"133","author":"Suga","year":"1993","journal-title":"Endocrinology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"17300","DOI":"10.1073\/pnas.0407894101","article-title":"Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs","volume":"101","author":"Tamura","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"8547","DOI":"10.1038\/s41598-019-44975-w","article-title":"Exogenous C-type natriuretic peptide therapy for impaired skeletal growth in a murine model of glucocorticoid treatment","volume":"9","author":"Ueda","year":"2019","journal-title":"Sci. Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12887-025-05478-y","article-title":"Identification and functional analysis of NPR2 truncating mutations in two Chinese families with short stature","volume":"25","author":"Wei","year":"2025","journal-title":"BMC Pediatr."},{"key":"B79","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1124\/jpet.114.218560","article-title":"Neutral endopeptidase-resistant C-Type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3\u2013Related dwarfism","volume":"353","author":"Wendt","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"25847","DOI":"10.1074\/jbc.m301223200","article-title":"Furin-mediated processing of Pro-C-type natriuretic peptide","volume":"278","author":"Wu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B81","doi-asserted-by":"publisher","first-page":"823861","DOI":"10.3389\/fgene.2022.823861","article-title":"Novel loss-of-function mutations in NPR2 cause acromesomelic dysplasia, maroteaux type","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Genet."},{"key":"B82","doi-asserted-by":"publisher","first-page":"bqaa008","DOI":"10.1210\/endocr\/bqaa008","article-title":"C-Type natriuretic peptide restores growth impairment under enzyme replacement in mice with mucopolysaccharidosis VII","volume":"161","author":"Yamashita","year":"2020","journal-title":"Endocrinology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10561-019-09760-z","article-title":"Integration of C-type natriuretic peptide gene-modified bone marrow mesenchymal stem cells with chitosan\/silk fibroin scaffolds as a promising strategy for articular cartilage regeneration","volume":"20","author":"Yang","year":"2019","journal-title":"Cell Tissue Bank."},{"key":"B84","doi-asserted-by":"publisher","first-page":"11695","DOI":"10.1074\/jbc.273.19.11695","article-title":"Natriuretic peptide regulation of endochondral ossification evidence for possible roles of the C-Type natriuretic peptide\/guanylyl Cyclase-B pathway","volume":"273","author":"Yasoda","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B85","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nm971","article-title":"Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway","volume":"10","author":"Yasoda","year":"2004","journal-title":"Nat. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1210\/en.2008-1676","article-title":"Systemic administration of C-Type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias","volume":"150","author":"Yasoda","year":"2009","journal-title":"Endocrinology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0196-9781(95)02099-3","article-title":"Binding of CNP-22 and CNP-53 to cultured mouse astrocytes and effects on cyclic GMP","volume":"17","author":"Yeung","year":"1996","journal-title":"Peptides"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e0216340","DOI":"10.1371\/journal.pone.0216340","article-title":"Foramen magnum stenosis and midface hypoplasia in C-type natriuretic peptide-deficient rats and restoration by the administration of human C-type natriuretic peptide with 53 amino acids","volume":"14","author":"Yotsumoto","year":"2019","journal-title":"PLoS ONE"}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1949456\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:08:06Z","timestamp":1790777286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1949456\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":89,"alternative-id":["10.3389\/fchem.2026.1949456"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2026.1949456","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1949456"}}